Byondis B.V., headquartered in the Netherlands, is a pioneering biopharmaceutical company specialising in the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2013, Byondis has rapidly established itself as a key player in the oncology sector, focusing on targeted therapies that enhance the efficacy and safety of cancer treatments. With a strong presence in Europe and expanding operations in the United States, Byondis is committed to advancing its proprietary technologies, including its unique linker and payload systems. The company’s flagship product, a novel ADC, exemplifies its dedication to improving patient outcomes through precision medicine. Byondis has garnered recognition for its scientific advancements and strategic partnerships, positioning itself as a leader in the biopharmaceutical landscape.
How does Byondis B.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Byondis B.V.'s score of 23 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Byondis B.V., headquartered in the Netherlands, currently does not have specific carbon emissions data available, as indicated by the absence of reported emissions figures. The company has not outlined any documented reduction targets or climate pledges, which suggests a lack of formal commitments to measurable climate action at this time. It is important to note that Byondis B.V. is a current subsidiary and may inherit emissions data and climate initiatives from its parent organisation. However, no specific details regarding such cascaded data or initiatives have been provided. In the context of the industry, companies are increasingly expected to set science-based targets and engage in transparent reporting of their carbon footprints. Byondis B.V. may need to consider establishing clear climate commitments and reduction strategies to align with these industry standards and expectations.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Byondis B.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
